Key facts
- MRM Health’s last known valuation is $67.1M (Sep 2025).
- It has raised $88.7M; the latest was Later Stage VC ($64.2M) in Sep 2025.
- Notable investors include Korys Investments, Société Fédérale de Participations et d'Investissement, VIB, BNP Paribas Fortis Private Equity, Ackermans & van Haaren — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for MRM Health
- ·The full record, as it builds
Funding rounds
No funding rounds for MRM Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MRM Health
Developer of a clinical-stage biopharmaceutical platform designed to create microbiome-based live biotherapeutic products to address chronic inflammatory diseases. The company offers a proprietary platform with advanced bioinformatics-guided strain design, optimized microbial consortia development and standardized manufacturing, enabling healthcare researchers and clinicians to explore new therapeutic approaches for patients with inflammatory bowel conditions and complex health challenges.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2020
- Employees
- 41
- Website
- mrmhealth.com/
- Ownership
- Privately Held (backing)
MRM Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MRM Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MRM Health in its N-PORT filings yet. We sweep new filings monthly.